ReviewJournal of clinical medicine2016
Advances in the Microbiome: Applications to Clostridium difficile Infection.
Review in Journal of clinical medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 34 citations in OpenAlex.
- An exploratoryMicrobiome research reports · 2024Review
- Clostridioides difficile infection in thoroughbred horses in Japan from 2010 to 2021.Scientific reports · 2023Article
- Review
- Urinary Tract Infections Caused by UropathogenicMicroorganisms · 2022Article
- Association between ribotype and clinical form of enterocolitis withExperimental and therapeutic medicine · 2022Article
- The microbiome impacts host hybridization and speciation.PLoS biology · 2021Article
- Gut microbiota composition in health-care facility-and community-onset diarrheic patients with Clostridioides difficile infection.Scientific reports · 2021Article
- Efficient protection of microorganisms for delivery to the intestinal tract by cellulose sulphate encapsulation.Microbial cell factories · 2020Article
- Genome-Based Comparison of Clostridioides difficile: Average Amino Acid Identity Analysis of Core Genomes.Microbial ecology · 2018Article
- Engineering microbes for targeted strikes against human pathogens.Cellular and molecular life sciences : CMLS · 2018Review
- Treatment of recurrentGastroenterology report · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile is a major cause of morbidity and mortality worldwide, causing over 400,000 infections and approximately 29,000 deaths in the United States alone each year. C. difficile is the most common cause of nosocomial diarrhoea in the developed world, and, in recent years, the emergence of hyper-virulent (mainly ribotypes 027 and 078, sometimes characterised by increased toxin production), epidemic strains and an increase in the number of community-acquired infections has caused further concern. Antibiotic therapy with metronidazole, vancomycin or fidaxomicin is the primary treatment for C. difficile infection (CDI). However, CDI is unique, in that, antibiotic use is also a major risk factor for acquiring CDI or recurrent CDI due to disruption of the normal gut microbiota. Therefore, there is an urgent need for alternative, non-antibiotic therapeutics to treat or prevent CDI. Here, we review a number of such potential treatments which have emerged from advances in the field of microbiome research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.